and pelvis remains the main site of local recurrence. We sought to investigate whether aggressiveness of bladder cancer correlated with washings in the pelvis & pneumo-peritoneum at different stages of robot-assisted radical cystectomy (RARC).
INTRODUCTION AND OBJECTIVES: Traditional cigarette smoking is a well-established cause of bladder cancer. E-cigarette use is gaining popularity in part due to the perception it represents a safer alternative to smoking. Initial studies have shown the composition of e-cigarette liquids to be complex and may contain nitrosamines, formaldehyde, acrolein, metals, and acetaldehyde many of which are known bladder carcinogens. We compared the urine of e-cigarette users to non-smoking, non e-cigarette using controls by liquid chromactographymass spectrometry (LC-MS) for known bladder carcinogens.
METHODS: Urine samples were collected from 13 e-cigarette users and 10 non-smoking, non e-cigarette using controls. Samples were acidified, hydrolyzed, extracted, dried and resuspended for LC-MS analysis. Five molecules known to be bladder carcinogens that are either present in traditional cigarettes or common solvents believed to be used in some e-cigarette formulations were targeted for analysis. These included benz(a)anthracene, benzo(a)pyrene, 1-hydroxypyrene, o-toluidine and 2-naphthylamine (limit of detection 10-100 ng/ml).
RESULTS: Subjects were predominantly male with a mean age of 39.4 years. All subjects had abstained completely by self-report from traditional cigarettes for at least 6 months prior to specimen collection ( Table 1) . Analysis of e-cigarette user urine was positive for two of the carcinogenic compounds, o-toluidine and 2-naphthylamine (limits of detection 100 ng/ml and 10 ng/ml respectively), in 12/13 e-cigarette users but none of the ten controls (Fischer's exact ¼ 0.0069). The other 3 tested urinary carcinogens were not identified.
CONCLUSIONS: E-cigarettes are historically unregulated with a wide variety of formulations. Previous studies have identified nitrosamines in low levels in e-cigarette formulations as well as a variety of solvents such as formaldehyde. Twelve of the 13 subjects studied had carcinogenic 2-naphtylamine and 0-toluidine present. Many of these subjects (9/13) were long term nonsmokers (>12 months). Further study is needed to clarify the safety profile of e-cigarettes and their contribution to the development of bladder cancer given the greater concentration of carcinogenic nitrosamines in the urine of e-cigarette users in this pilot study. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1179 that tumor exosomes play in cancer development, metastasis and drug resistance. Tumor cells have been shown to selectively package certain proteins and RNA material into exosomes for the purpose of cell to cell communication. After internalization, recipient cells show altered gene expression, which in turn, modifies their invasiveness, apoptotic rate and sensitivity to therapeutic drugs. Few studies have examined the role of exosomal microRNAs (miRNA) in transference of drug resistance in bladder cancer. We hypothesize, that specific miRNAs have distinct roles in the establishment of chemoresistance. Here we strive to identify exosomal miRNAs profiles and their roles in Cisplatin, Gemcitabine and Cisplatin/Gemcitabine chemoresistance in bladder cancer. METHODS: Three resistant sublines of the human CUB III bladder carcinoma cell line were developed by gradually exposing the cells to increasing doses of Gemcitabine, Cisplatin or a combination of Gemcitabine and Cisplatin, over a period of 6 months. Exosomes were harvested and characterized by nanoparticle tracking analysis. Exosomal miRNAs were profiled via qRT-PCR array analysis. These distinct exosomal miRNA signatures were investigated in several additional bladder carcinoma resistant cell lines.
RESULTS: Chemoresistant CUB III cells exhibit distinct miRNA profiles within their exosomes, which is unique depending on the drug of treatment. Of the 759 miRNA profiled, sixteen were differentially expressed (at least two-fold) across all the CUBIII resistant sublines relative to their parental line. Our data showed that 10 miRs were consistently down-regulated and 6 miRNAs were up regulated. Among the differentially expressed exosomal miRNAs in the resistant sublines, miR-Let-7i-3p was the most significantly down-regulated while miR-21-5p was the highest up-regulated compared to their chemosensitive counterpart.
CONCLUSIONS: Our findings demonstrate that for each chemotherapeutic drug, resistant cells had differentially expressed miRNA profiles within their exosomes. Many of these miRNAs have been shown to play a role in oncogenesis or the development of drug resistance in other tumor types. After further validation these exosomal miRNAs may have utility as predictive biomarkers of treatment response and possibly as therapeutic targets to enhance drug response.
Source of Funding: NONE

MP88-16
TARGETED EXOSOME-MEDIATED DELIVERY OF SURVIVIN SIRNA FOR THE TREATMENT OF BLADDER CANCER Rong Yang*, Xiang Yan, Shiwei Zhang, Hongqian Guo, Nanjing, China, People's Republic of INTRODUCTION AND OBJECTIVES: Bladder cancer is the most common malignancy of urogenital system and one of the major causes of death in Chinese cancer patients. Small RNAs (sRNA) are potential therapeutic drugs for bladder cancers. However, it is still difficult to transport sRNAs stably in the body. Cell-derived exosomes have been demonstrated to be efficient carriers of small RNAs to neighbouring or distant cells, highlighting the preponderance of exosomes as carriers for gene therapy over other artificial delivery tools.
METHODS: In the present study, we employed modified exosomes expressing the iRGD peptide (a tumor-penetrating peptide) on the membrane surface to deliver Survivin siRNA into bladder cancer in a mouse xenograft tumor model. qPCR and western blotting were used to determine the expression of siRNA and survivin in tumor tissues.
RESULTS: We found that Survivin siRNA could be efficiently packaged into iRGD modified exosomes and was associated with argonaute 2 (AGO2) in exosomes. These exosomes efficiently and specifically delivered Survivin siRNA into 5637 bladder cancer cells and the mouse xenograft tumor. Functionally, Survivin siRNA-loaded iRGD exosomes significantly reduced Survivin mRNA and protein levels in bladder cancer cells. Sebsequently, Survivin siRNA delivered by the iRGD modified exosomes strongly inhibited the growth of the mouse xenograft tumor.
CONCLUSIONS: In conclusion, our results demonstrate that targeted iRGD exosomes can efficiently transfer siRNA to bladder cancer and mediate the growth inhibiton of bladder cancer by downregulating Survivin expression levels. Our study provides a brand new strategy to treat bladder cancer.
Source of Funding: China Postdoctoral Science Foundation (2016M591831)
MP88-17 INTRODUCTION AND OBJECTIVES: Upper tract urothelial carcinomas (UTUC) are treated similarly to urothelial carcinoma of the bladder (UCB). UTUC demonstrates a more aggressive clinical course which may be explained by significant differences in mutational frequencies between UTUC and UCB that were reported using a customized exon capture sequencing assay (the MSK-IMPACTTM
